Development, License And Commercialization Agreement Sample Contracts

Adamis Pharmaceuticl – [*Designates Portions of This Document Have Been Omitted Pursuant to a Request for Confidential Treatment Filed Separately With the Commission] DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (August 15th, 2016)

THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this "Agreement") is made and entered into on May 9, 2016 (the "Effective Date"), by and between Watson Laboratories, Inc., a Nevada corporation ("Watson"), on the one hand, and Adamis Pharmaceuticals Corporation, a company incorporated under the laws of Delaware ("Adamis"), on the other hand. Watson and Adamis shall each sometimes be referred to herein as a "Party" and collectively as the "Parties."

Agile Therapeutics Inc – Development, License and Commercialization Agreement (May 5th, 2014)

This Development, License and Commercialization Agreement (this Agreement) is entered into as of October 18, 2006 (the Effective Date) between Corium International, Inc., a Delaware corporation having its principal place of business at 2686 Middlefield Road, Redwood City, CA 94063, (Corium), and Agile Therapeutics, Inc., a Delaware corporation, having its principal place of business at 366 Wall Street, Princeton, NJ 08540, (Agile).

Corium International, Inc. – Development, License and Commercialization Agreement (March 24th, 2014)

This Development, License and Commercialization Agreement (this Agreement) is entered into as of October 18, 2006 (the Effective Date) between Corium International, Inc., a Delaware corporation having its principal place of business at 2686 Middlefield Road, Redwood City, CA 94063, (Corium), and Agile Therapeutics, Inc., a Delaware corporation, having its principal place of business at 366 Wall Street, Princeton, NJ 08540, (Agile).

Agile Therapeutics Inc – Development, License and Commercialization Agreement (March 17th, 2014)

This Development, License and Commercialization Agreement (this Agreement) is entered into as of October 18, 2006 (the Effective Date) between Corium International, Inc., a Delaware corporation having its principal place of business at 2686 Middlefield Road, Redwood City, CA 94063, (Corium), and Agile Therapeutics, Inc., a Delaware corporation, having its principal place of business at 366 Wall Street, Princeton, NJ 08540, (Agile).

Corium International, Inc. – Development, License and Commercialization Agreement (March 3rd, 2014)

This Development, License and Commercialization Agreement (this Agreement) is entered into as of October 18, 2006 (the Effective Date) between Corium International, Inc., a Delaware corporation having its principal place of business at 2686 Middlefield Road, Redwood City, CA 94063, (Corium), and Agile Therapeutics, Inc., a Delaware corporation, having its principal place of business at 366 Wall Street, Princeton, NJ 08540, (Agile).

*** OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTION 240.24b-2 AMENDMENT Ndeg4 TO PRODUCT RESEARCH, DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (January 2nd, 2014)

a corporation organized and existing under the laws of Delaware, with registered office at 18 Desbrosses Street, New York, NY 10013, USA

AMENDMENT Ndeg2 TO PRODUCT RESEARCH, DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (This "Amendment") (February 22nd, 2013)

a corporation organized and existing under the laws of Delaware, with registered office at 18 Desbrosses Street, New York, NY 10013, USA

Product Research, Development, License and Commercialization Agreement (September 27th, 2012)

This Product Research, Development, License and Commercialization Agreement (this "Agreement") is effective as of August 1st, 2011 (the "Effective Date") and is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with registered office at 18 Desbrosses Street, New-York 10013 NY, USA ("INTERCEPT") on the one hand and LES LABORATOIRES SERVIER, a corporation organized and existing under the laws of France, with registered office at 22 rue Garnier, 92578 Neuilly-sur-Seine cedex, France and INSTITUT DE RECHERCHES SERVIER, a corporation organized and existing under the laws of France, with registered office at 3 rue de la Republique, 92150 Suresnes, France (these two entities are jointly referred to as "SERVIER") on the other hand.

AMENDMENT Ndeg1 TO PRODUCT RESEARCH, DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (September 4th, 2012)

a corporation organized and existing under the laws of Delaware, with registered office at 18 Desbrosses Street, New-York 10013 NY, USA

Product Research, Development, License and Commercialization Agreement (September 4th, 2012)

This Product Research, Development, License and Commercialization Agreement (this "Agreement") is effective as of August 1st, 2011 (the "Effective Date") and is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with registered office at 18 Desbrosses Street, New-York 10013 NY, USA ("INTERCEPT") on the one hand and LES LABORATOIRES SERVIER, a corporation organized and existing under the laws of France, with registered office at 22 rue Garnier, 92578 Neuilly-sur-Seine cedex, France and INSTITUT DE RECHERCHES SERVIER, a corporation organized and existing under the laws of France, with registered office at 3 rue de la Republique, 92150 Suresnes, France (these two entities are jointly referred to as "SERVIER") on the other hand.

Indevus Pharmaceuticals Inc. – DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT by and Between INDEVUS PHARMACEUTICALS, INC. And TEVA PHARMACEUTICAL INDUSTRIES LTD. (December 11th, 2008)

THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (the Agreement) is made as of September 25, 2008 (Agreement Date), by and between INDEVUS PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 33 Hayden Avenue, Lexington, MA 02421, United States (Indevus) and TEVA PHARMACEUTICAL INDUSTRIES LTD., a limited liability company existing under the laws of Israel and having its principal office at Petah Tiqva 49131, Israel (Teva).

Sunovion – Development, License and Commercialization Agreement (November 9th, 2007)

This DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (Agreement) is entered into between Sepracor Inc., a company organized under the laws of the State of Delaware, United States, and having its principal place of business at 84 Waterford Drive, Marlborough, MA 01752-7010, United States, and Glaxo Group Limited, a company organized under the laws of England & Wales and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (GSK).

Redacted Portions Are Indicated by [****]. DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT Dated May 13, 2005 by and Between BioMarin Pharmaceutical Inc. And Ares Trading S.A., (July 6th, 2005)

This DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (Agreement) is made effective as of the 13th day of May, 2005 (the Effective Date) by and between BioMarin Pharmaceutical Inc., a corporation organized under the laws of Delaware and having its principal place of business at 105 Digital Drive, Novato, California 94949 (BioMarin) and Ares Trading S.A., a corporation organized under the laws of Switzerland and having a principal place of business at Zone Industrielle de lOuriettaz, 1170 Aubonne, Switzerland (Serono). BioMarin and Serono are each referred to herein as a Party and collectively as the Parties.